Are vasodilators still indicated in the treatment of severe aortic regurgitation?

Jocelyn Inano, Maurice E Sarano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalCurrent Cardiology Reports
Volume9
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Aortic Valve Insufficiency
Vasodilator Agents
Ventricular Remodeling
Therapeutics
Life Expectancy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Are vasodilators still indicated in the treatment of severe aortic regurgitation? / Inano, Jocelyn; Sarano, Maurice E.

In: Current Cardiology Reports, Vol. 9, No. 2, 04.2007, p. 87-92.

Research output: Contribution to journalArticle

@article{d83e0d9d955a498797d13a0d59dd31fc,
title = "Are vasodilators still indicated in the treatment of severe aortic regurgitation?",
abstract = "Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.",
author = "Jocelyn Inano and Sarano, {Maurice E}",
year = "2007",
month = "4",
doi = "10.1007/BF02938333",
language = "English (US)",
volume = "9",
pages = "87--92",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Are vasodilators still indicated in the treatment of severe aortic regurgitation?

AU - Inano, Jocelyn

AU - Sarano, Maurice E

PY - 2007/4

Y1 - 2007/4

N2 - Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.

AB - Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.

UR - http://www.scopus.com/inward/record.url?scp=34247880485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247880485&partnerID=8YFLogxK

U2 - 10.1007/BF02938333

DO - 10.1007/BF02938333

M3 - Article

C2 - 17430674

AN - SCOPUS:34247880485

VL - 9

SP - 87

EP - 92

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 2

ER -